E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systemic Juvenile Idiopathic Arthritis (sJIA) |
Artritis idiopatica Juvenil Sistemica (AIJS) |
|
E.1.1.1 | Medical condition in easily understood language |
Children with sJIA have arthritis and often have daily fever with rash, in addition to inflammation of the lining of the lung or heart, liver or spleen enlargement, or enlargement of the lymph nodes |
Niños con AIJS tienen artritis y amenudo fiebre diaria con rash, además de inflamación de la mucosa de pulmones o corazón, agrandamiento del hígado o bazo, o agrandamiento de los nodulos linfáticos |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10059176 |
E.1.2 | Term | Juvenile idiopathic arthritis |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective - To characterize the pharmacokinetics of subcutaneous tocilizumab (SC TCZ) in patients with sJIA |
El objetivo farmacocinético (FC) de este estudio es definir la farmacocinética de TCZ SC en pacientes con AIJS. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives: - To evaluate the pharmacodynamics of SC TCZ in patients with sJIA - To evaluate the safety of SC TCZ in patients with sJIA
Exploratory Objective To describe the efficacy of SC TCZ in patients with sJIA |
El objetivo farmacodinámico (FD) de este estudio es evaluar la farmacodinamia de TCZ SC en pacientes con AIJS. El objetivo de seguridad de este estudio es evaluar la seguridad de TCZ SC en pacientes con AIJS. El objetivo exploratorio de este estudio es describir la eficacia de TCZ SC en pacientes con AIJS. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Children 1-17 years of age - Diagnosis systemic juvenile idiopathic arthritis - Inadequate clinical response (in the opinion of the treating physician) to NSAIDs and corticosteroids - Concurrent treatment with DMARDs (including methotrexate [MTX]), NSAIDs, and oral corticosteroids is permitted at the discretion of the investigator. - Discontinuation of biologic agents (other than tocilizumab if the patient is receiving IV TCZ) for 4 days to 20 weeks prior to baseline depending on biologic agent |
Tener edades comprendidas entre 1 y 17 años AIJS diagnosticada Haber presentado una respuesta clínica inadecuada (de acuerdo con la opinión del médico responsable del tratamiento) a un tratamiento previo con AINEs y corticosteroides. Tratamiento concomitante con DMARDs (incluido MTX) AINEs, y corticosteroides orales, se permiten a criterio del investigador Interrupción del tratamiento con agentes biologicos (diferentes a TCZ IV) de 4 días a 20 semanas previas al inicio del tratamiento en función del agente biologico |
|
E.4 | Principal exclusion criteria |
- Prior discontinuation of IV TCZ because of inadequate clinical response or safety events - Patients with poorly controlled disease (in the opinion of the treating physician) despite current treatment with IV TCZ - sJIA that is well controlled by any treatment agent other than TCZ (JADAS-71?3.8 with no fever) - Patients who are wheelchair-bound or bedridden - Any other auto-immune, rheumatic disease, or overlapping syndrome other than sJIA |
Suspensión de un tratamiento previo con TCZ IV debido a respuesta clínica inadecuada o problemas de seguridad (incluyendo reacciones de hipersensibilidad). Enfermedad mal controlada (de acuerdo con la opinión del médico responsable del tratamiento) a pesar del tratamiento actual con TCZ IV AIJS bien controlada con cualquier agente terapéutico, a excepción de TCZ (puntuación JADAS-71 menor o igual 3,8 en ausencia de fiebre). Pacientes en silla de ruedas o encamados. Presentar cualquier otra enfermedad autoinmune, reumática o síndrome de superposición distintos de AIJS |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Serum TCZ concentration and population PK model-predicted PK exposures (AUC, Cmax and Cmin) for the QW and Q10D dosing regimens at steady state |
Concentración sérica de TCZ y exposiciones FC previstas basadas en un modelo FC poblacional (área bajo la curva de la concentración-tiempo [AUC], concentración plasmática máxima [Cmax] y Cmin) de los regímenes de administración CS y C10D en estado de equilibrio. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Fixed timepoints during the first 14 weeks of the study |
Tiempos fijados durante las primeras 14 semanas del estudio |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints: - Serum IL-6 and soluble IL-6R (sIL-6R) levels, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) - The incidence and severity of adverse events (including local injection-site reactions) and serious adverse events - The incidence and severity of adverse events of special interest - The incidence and severity of clinical laboratory abnormalities - The incidence of anti-TCZ antibodies
Exploratory endpoints: - Juvenile Arthritis Disease Activity Score (JADAS)-71 - Inactive disease and clinical remission - Childhood Health Assessment Questionnaire (CHAQ) |
Concentraciones séricas de interleuquina 6 (IL-6) y del receptor de IL-6 soluble (sIL-6R), proteína C reactiva (PCR) y velocidad de sedimentación globular (VSG) Incidencia de anticuerpos anti-TCZ Incidencia de AA (incluyendo reacciones locales en la zona de inyección) y acontecimientos adversos graves Incidencia y severidad de los acontecimientos adversos de especial interés Incidencia y severidad de las anomalías de laboratorio clínico Las variables de valoración exploratorias de este estudio son las siguientes: JADAS-71 Enfermedad inactiva y remisión clínica Childhood Health Assessment Questionnaire (CHAQ) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints: - Pharmacodynamic endpoints will be evaluated at fixed timepoints during the first 14 weeks of the study [Weeks 0-14] - Adverse events, adverse events of special interest and clinical laboratory abnormalities will be recorded for the entire duration of the study [Weeks 0-52] - The presence of anti-TCZ antibodies will be evaluated at baseline and at regular intervals with event-driven testing in cases of anaphylaxis, serious hypersensitivity events, or any hypersensitivity event (including non-serious events) leading to treatment withdrawal (at the time of the event and at least 6 weeks after the event)
Exploratory endpoints: - All endpoints will be measured for the duration of the study [Weeks 0-52] |
Se realizarán evaluaciones FC para evaluar los regímenes de administración durante las 14 primeras semanas del estudio. Los acontecimientos adversos y los acontecimientos adversos de especial interés y anomalías de laboratorio serán registradas durante toda la duración del ensayo (0-52 semanas). La presencia de anticuerpos anti-TCZ será evaluada desde el inicio y a intervalos regulares en casos de anafilaxia, hipersensibilidad grave o cualquier evento de hipersensibilidad (incluyendo eventos no graves) hacia el retiro del tratamiento (en el momento del evento y al menos 6 semanas después del evento) Variables de evaluación exploratoria: -Todas las variables de evaluación exploratoria se medirán durante la duración del estudio (0-52 semanas) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
dose evaluation in paediatric patients (adaptive design) |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
France |
Germany |
Italy |
Mexico |
Russian Federation |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study will occur when the last patient completes the last scheduled visit of the study or if the sponsor decides, for whatever reason, to discontinue the study |
El estudio terminará cuando el último paciente complete la última visita programada del estudio o si el promotor del mismo decide, por cualquier razón, interumpir el estudio |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 21 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 21 |